1. Home
  2. BDSX vs PFO Comparison

BDSX vs PFO Comparison

Compare BDSX & PFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BDSX
    SELLHOLDBUYas of 20 hours ago
  • PFO
    SELLHOLDBUYas of 20 hours ago
  • Stock Information
  • Founded
  • BDSX 2005
  • PFO 1991
  • Country
  • BDSX United States
  • PFO United States
  • Employees
  • BDSX N/A
  • PFO N/A
  • Industry
  • BDSX Precision Instruments
  • PFO Finance Companies
  • Sector
  • BDSX Health Care
  • PFO Finance
  • Exchange
  • BDSX Nasdaq
  • PFO Nasdaq
  • Market Cap
  • BDSX 115.4M
  • PFO 120.4M
  • IPO Year
  • BDSX 2020
  • PFO N/A
  • Fundamental
  • Price
  • BDSX $0.63
  • PFO $9.22
  • Analyst Decision
  • BDSX Strong Buy
  • PFO
  • Analyst Count
  • BDSX 3
  • PFO 0
  • Target Price
  • BDSX $2.93
  • PFO N/A
  • AVG Volume (30 Days)
  • BDSX 270.4K
  • PFO 31.8K
  • Earning Date
  • BDSX 05-07-2025
  • PFO 01-01-0001
  • Dividend Yield
  • BDSX N/A
  • PFO 6.51%
  • EPS Growth
  • BDSX N/A
  • PFO N/A
  • EPS
  • BDSX N/A
  • PFO N/A
  • Revenue
  • BDSX $71,323,000.00
  • PFO N/A
  • Revenue This Year
  • BDSX $32.90
  • PFO N/A
  • Revenue Next Year
  • BDSX $24.65
  • PFO N/A
  • P/E Ratio
  • BDSX N/A
  • PFO N/A
  • Revenue Growth
  • BDSX 45.30
  • PFO N/A
  • 52 Week Low
  • BDSX $0.59
  • PFO $6.90
  • 52 Week High
  • BDSX $2.04
  • PFO $8.51
  • Technical
  • Relative Strength Index (RSI)
  • BDSX 31.91
  • PFO 52.60
  • Support Level
  • BDSX $0.59
  • PFO $9.12
  • Resistance Level
  • BDSX $0.75
  • PFO $9.23
  • Average True Range (ATR)
  • BDSX 0.08
  • PFO 0.08
  • MACD
  • BDSX -0.01
  • PFO -0.00
  • Stochastic Oscillator
  • BDSX 12.53
  • PFO 55.56

Stock Price Comparison Chart: BDSX vs PFO

BDSX
PFO
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025April02468101214161820BDSX VS PFO

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated

Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use